TY - JOUR
T1 - Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery
AU - Lee, Hyukjin
AU - Lytton-Jean, Abigail K.R.
AU - Chen, Yi
AU - Love, Kevin T.
AU - Park, Angela I.
AU - Karagiannis, Emmanouil D.
AU - Sehgal, Alfica
AU - Querbes, William
AU - Zurenko, Christopher S.
AU - Jayaraman, Muthusamy
AU - Peng, Chang G.
AU - Charisse, Klaus
AU - Borodovsky, Anna
AU - Manoharan, Muthiah
AU - Donahoe, Jessica S.
AU - Truelove, Jessica
AU - Nahrendorf, Matthias
AU - Langer, Robert
AU - Anderson, Daniel G.
N1 - Funding Information:
This work was supported by the National Institutes of Health (EB000244), the Center for Cancer Nanotechnology Excellence (U54 CA151884), Alnylam Pharmaceuticals and the National Research Foundation of Korea (NRF-2011-357-D00063). The authors thank J. Hong and C. Hong for figure drawing, and J.B. Lee and A. Schroeder for helpful discussions.
PY - 2012/6
Y1 - 2012/6
N2 - Nanoparticles are used for delivering therapeutics into cells. However, size, shape, surface chemistry and the presentation of targeting ligands on the surface of nanoparticles can affect circulation half-life and biodistribution, cell-specific internalization, excretion, toxicity and efficacy. A variety of materials have been explored for delivering small interfering RNAs (siRNAs)ĝa therapeutic agent that suppresses the expression of targeted genes. However, conventional delivery nanoparticles such as liposomes and polymeric systems are heterogeneous in size, composition and surface chemistry, and this can lead to suboptimal performance, a lack of tissue specificity and potential toxicity. Here, we show that self-assembled DNA tetrahedral nanoparticles with a well-defined size can deliver siRNAs into cells and silence target genes in tumours. Monodisperse nanoparticles are prepared through the self-assembly of complementary DNA strands. Because the DNA strands are easily programmable, the size of the nanoparticles and the spatial orientation and density of cancer-targeting ligands (such as peptides and folate) on the nanoparticle surface can be controlled precisely. We show that at least three folate molecules per nanoparticle are required for optimal delivery of the siRNAs into cells and, gene silencing occurs only when the ligands are in the appropriate spatial orientation. In vivo, these nanoparticles showed a longer blood circulation time (t 1/2 24.2 min) than the parent siRNA (t 1/2 6 min).
AB - Nanoparticles are used for delivering therapeutics into cells. However, size, shape, surface chemistry and the presentation of targeting ligands on the surface of nanoparticles can affect circulation half-life and biodistribution, cell-specific internalization, excretion, toxicity and efficacy. A variety of materials have been explored for delivering small interfering RNAs (siRNAs)ĝa therapeutic agent that suppresses the expression of targeted genes. However, conventional delivery nanoparticles such as liposomes and polymeric systems are heterogeneous in size, composition and surface chemistry, and this can lead to suboptimal performance, a lack of tissue specificity and potential toxicity. Here, we show that self-assembled DNA tetrahedral nanoparticles with a well-defined size can deliver siRNAs into cells and silence target genes in tumours. Monodisperse nanoparticles are prepared through the self-assembly of complementary DNA strands. Because the DNA strands are easily programmable, the size of the nanoparticles and the spatial orientation and density of cancer-targeting ligands (such as peptides and folate) on the nanoparticle surface can be controlled precisely. We show that at least three folate molecules per nanoparticle are required for optimal delivery of the siRNAs into cells and, gene silencing occurs only when the ligands are in the appropriate spatial orientation. In vivo, these nanoparticles showed a longer blood circulation time (t 1/2 24.2 min) than the parent siRNA (t 1/2 6 min).
UR - http://www.scopus.com/inward/record.url?scp=84863726330&partnerID=8YFLogxK
U2 - 10.1038/nnano.2012.73
DO - 10.1038/nnano.2012.73
M3 - Article
C2 - 22659608
AN - SCOPUS:84863726330
SN - 1748-3387
VL - 7
SP - 389
EP - 393
JO - Nature Nanotechnology
JF - Nature Nanotechnology
IS - 6
ER -